2021
Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial
Cowan R, Scarisbrick J, Zinzani P, Nicolay J, Sokol L, Pinter‐Brown L, Quaglino P, Iversen L, Dummer R, Musiek A, Foss F, Ito T, Rosen J, Medley M. Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. Journal Of The European Academy Of Dermatology And Venereology 2021, 35: 2225-2238. PMID: 34273208, PMCID: PMC9290719, DOI: 10.1111/jdv.17523.Peer-Reviewed Original ResearchConceptsObjective response rateProgression-free survivalBlood tumor burdenSézary syndromeMycosis fungoidesB2 patientsBlood involvementTumor burdenInvestigator-assessed progression-free survivalSuperior objective response rateTreatment-emergent adverse eventsRefractory mycosis fungoidesGreater clinical benefitCD8 ratioAdverse eventsSystemic therapyClinical benefitMogamulizumabPatient responseSustained reductionNext treatmentPatientsResponse rateCell countVorinostat
2002
Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease
Gorgun G, Miller KB, Foss FM. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease. Blood 2002, 100: 941-947. PMID: 12130506, DOI: 10.1182/blood-2002-01-0068.Peer-Reviewed Original ResearchConceptsMixed lymphocyte reactionAntigen-presenting dendritic cellsDendritic cellsT cellsChronic graftHost diseaseClinical responseDC populationsActivity of DCsAllogeneic bone marrow transplantationCD4/CD8 ratioMonocytic dendritic cellsAllogeneic T cellsEffector T cellsNatural killer cellsBone marrow transplantationTh2 cytokine profileChronic GVHDCD8 ratioCytokine profileECP therapyImmunologic mechanismsLymphocyte subpopulationsEffector lymphocytesKiller cells